Notice of Intent contact activation pathway function blocking antibody AB023
Closed Special Notice Posted
- Solicitation number
- HT9426-26-NOI-WS03
- Agency
- Not on record
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- Jbsa Ft Sam Houston, Texas 78234, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Health Agency, supporting the United States Army Institute of Surgical Research, issued a notice of intent on June 23, 2026 to procure contact activation pathway function blocking antibody AB023 via sole-source award to Oregon Health & Science University, with a July 9, 2026 deadline for interested parties to submit capability information. The contemplated contract does not represent a competitive procurement; DHA issued this notice to satisfy Federal Acquisition Regulation (FAR) requirements for sole-source justification and will evaluate responses only to determine whether to conduct competitive procurement instead. An earlier RFI (HT9426-26-RFI-WS03) posted June 12–18, 2026 on SAM.gov received no responses. Responsible parties must submit capability statements by July 9, 2026 at 12:00 PM Eastern Time via email to william.a.shortall.civ@health.mil to establish their ability to meet the requirement. The requirement falls under NAICS 541714 (Research and Development in Biotechnology, except Nanobiotechnology) with a 1,000-employee size standard, and PSC 6505 (Drugs and Biologicals). DHA assumes no responsibility for costs incurred in preparing responses, and the Government retains sole discretion over whether to proceed with competitive procurement based on capability submissions received.
Notice text
The Defense Health Agency (DHA), Defense Health Agency Contracting Activity (DHACA), 808 Schreider Street, Fort Detrick, MD 21702, in support of the United States Army Institute of Surgical Research (USAISR) is issuing this notice of intent to procure items via Sole Source negotiation through the award of a contract to Oregon Health & Science University (OHSU). Under the contemplated award, Oregon Health & Science University, 3303 SW Bond Avenue, Portland, Oregon 97239, will provide contact activation pathway function blocking antibody AB023. Request for Information (RFI) HT9426-26-RFI-WS03 was posted on https://sam.gov from 12 June 2026 to 18 June 2026 with no responses received.
The North American Industry Classification System (NAICS) for this requirement is 541714 with a size standard of 1,000 employees.
THIS NOTICE OF INTENT IS NOT A REQUEST FOR COMPETITIVE QUOTATIONS. Responsible, interested parties may identify their interest by submitting capability information by Thursday, 09 July 2026 at 12:00PM Eastern Standard Time in order to establish the ability of the responder to meet this requirement. A determination by the Government to not compete this proposed contract based upon responses received to this notice is solely within the discretion of the Government. Information received will be considered for the sole purpose of determining whether to conduct a competitive procurement. The Government will not be responsible for any costs associated with preparing responses to this notification. All inquiries must be submitted via email to william.a.shortall.civ@health.mil by 12PM Eastern Standard Time on 09 July 2026.
Similar open opportunities
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity